12 December 2019

Clarification of the Trading Halt

The purpose of the trading halt is to prepare the release on the reporting of results following the completion of dosing in all patients in the Company's ATL1102 for DMD Phase II clinical trial.

Unless otherwise requested by the Company, ANP requests the trading halt to remain in place until the earlier of the release of an announcement or the morning of Monday 16 December 2019.

On behalf of the Board



Phillip Hains
Company Secretary

This release was authorised by the Company Secretary